ATE244506T1 - Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein - Google Patents

Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein

Info

Publication number: ATE244506T1
Authority: AT; Austria
Prior art keywords: associated protein; multidrug resistance; mrp; methods; protein expression
Prior art date: 1993-10-18

Application number

AT94930472T

Other languages

English (en)

Inventor

Edgardo Baracchini Jr

Clarence Frank Bennett

Original Assignee

Isis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-10-18

Filing date

1994-09-23

Publication date

2003-07-15

1994-09-23 Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc

2003-07-15 Application granted granted Critical

2003-07-15 Publication of ATE244506T1 publication Critical patent/ATE244506T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 3
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
102000004855 Multi drug resistance-associated proteins Human genes 0.000 abstract 6
108090001099 Multi drug resistance-associated proteins Proteins 0.000 abstract 6
238000000034 method Methods 0.000 abstract 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
230000036457 multidrug resistance Effects 0.000 abstract 2
241001465754 Metazoa Species 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
238000002512 chemotherapy Methods 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
230000004060 metabolic process Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AT94930472T 1993-10-18 1994-09-23 Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein ATE244506T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/136,811 US5510239A (en)	1993-10-18	1993-10-18	Oligonucleotide modulation of multidrug resistance-associated protein
PCT/US1994/010827 WO1995010938A1 (en)	1993-10-18	1994-09-23	Oligonucleotide modulation of multidrug resistance-associated protein

Publications (1)

Publication Number	Publication Date
ATE244506T1 true ATE244506T1 (de)	2003-07-15

Family

ID=22474477

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94930472T ATE244506T1 (de)	1993-10-18	1994-09-23	Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein

Country Status (8)

Country	Link
US (1)	US5510239A (de)
EP (1)	EP0788307B1 (de)
JP (1)	JP2937481B2 (de)
AT (1)	ATE244506T1 (de)
AU (1)	AU678628B2 (de)
CA (1)	CA2174315C (de)
DE (1)	DE69432934T2 (de)
WO (1)	WO1995010938A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040142899A1 (en) *	1990-01-11	2004-07-22	Isis Pharmaceuticals, Inc.	Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6753423B1 (en)	1990-01-11	2004-06-22	Isis Pharmaceuticals, Inc.	Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US5683987A (en) *	1994-07-12	1997-11-04	The Board Of Regents Of The University Of Nebraska	Therapeutic oligonucleotides targeting the human MDR1 and MRP genes
US5866699A (en) *	1994-07-18	1999-02-02	Hybridon, Inc.	Oligonucleotides with anti-MDR-1 gene activity
US6645943B1 (en)	1994-10-25	2003-11-11	Hybridon, Inc.	Method of down-regulating gene expression
US6608035B1 (en) *	1994-10-25	2003-08-19	Hybridon, Inc.	Method of down-regulating gene expression
US6156535A (en) *	1995-08-04	2000-12-05	University Of Ottawa	Mammalian IAP gene family, primers, probes, and detection methods
US6346398B1 (en) *	1995-10-26	2002-02-12	Ribozyme Pharmaceuticals, Inc.	Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US6133437A (en) *	1997-02-13	2000-10-17	Apoptogen, Inc.	Modulation of IAPs for the treatment of proliferative diseases
US7309692B1 (en) *	1996-07-08	2007-12-18	Board Of Regents, The University Of Texas System	Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
EP1283268A3 (de) *	1996-08-23	2004-01-02	Ludwig Institute For Cancer Research	Rekombinantes Vasculäres Endothelzellen Wachstumsfaktor D (VEGF-D)
US6111085A (en) *	1996-09-13	2000-08-29	Isis Pharmaceuticals, Inc.	Carbamate-derivatized nucleosides and oligonucleosides
US6001991A (en) *	1996-10-04	1999-12-14	Isis Pharmaceuticals Inc.	Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US6127533A (en) *	1997-02-14	2000-10-03	Isis Pharmaceuticals, Inc.	2'-O-aminooxy-modified oligonucleotides
US6576752B1 (en)	1997-02-14	2003-06-10	Isis Pharmaceuticals, Inc.	Aminooxy functionalized oligomers
US6172209B1 (en)	1997-02-14	2001-01-09	Isis Pharmaceuticals Inc.	Aminooxy-modified oligonucleotides and methods for making same
US5902881A (en) *	1997-03-03	1999-05-11	Isis Pharmaceuticals, Inc.	Reagent useful for synthesizing sulfurized oligonucleotide analogs
US5760209A (en) *	1997-03-03	1998-06-02	Isis Pharmaceuticals, Inc.	Protecting group for synthesizing oligonucleotide analogs
US6162616A (en)	1997-04-16	2000-12-19	Millennium Pharmaceuticals, Inc.	Multidrug resistance-associated polypeptide
US20030220234A1 (en) *	1998-11-02	2003-11-27	Selvaraj Naicker	Deuterated cyclosporine analogs and their use as immunodulating agents
US6410041B1 (en) *	1998-04-28	2002-06-25	Trustees Of Tufts College	Culturing cells in presence of amphipathic weak bases and/or cations and multiple drug resistance inhibitor containing reserpine
US6077709A (en)	1998-09-29	2000-06-20	Isis Pharmaceuticals Inc.	Antisense modulation of Survivin expression
NZ512244A (en)	1998-11-12	2003-12-19	Invitrogen Corp	Polycationic transfection reagents for introducing anions into a cell
US6492111B1 (en) *	1998-11-25	2002-12-10	Isis Pharmaceuticals, Inc.	In situ binary synthesis of biologically effective molecules
EP1141278B1 (de) *	1998-12-30	2008-02-27	Oligos Etc. Inc.	Therapeutische pde4d phosphodiesterase inhibitoren
US6380161B1 (en) *	1999-06-21	2002-04-30	Inkine Pharmaceutical Company, Inc.	Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
US6147200A (en) *	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
US6673917B1 (en) *	2000-09-28	2004-01-06	University Of Ottawa	Antisense IAP nucleic acids and uses thereof
EP1337664A4 (de) *	2000-10-27	2005-01-19	Invitrogen Corp	Verfahren zur einführung von antisense-oligonukleotiden in eukaryontische zellen
EP1414841B1 (de)	2001-07-10	2012-11-14	Lakewood-Amedex, Inc	Oligonukleotidhaltige pharmakologische zusammensetzungen und deren verwendung
MXPA04003625A (es) *	2001-10-19	2004-12-02	Sotechnika Inc	Sintesis de analogos de ciclosporina.
US20030191075A1 (en) *	2002-02-22	2003-10-09	Cook Phillip Dan	Method of using modified oligonucleotides for hepatic delivery
AU2003219432B2 (en) *	2002-03-27	2010-04-01	Pharmascience Inc.	Antisense IAP nucleobase oligomers and uses thereof
FR2850971B1 (fr) *	2003-02-10	2006-08-11	Aventis Pharma Sa	Oligonucleotide antisens inhibant l'expression de la proteine ob-rgrp et procede de detection de composes modifiant l'interaction entre la famille de la proteine ob-rgrp et le recepteur de la leptine
US8012944B2 (en) *	2003-10-30	2011-09-06	Pharmascience Inc.	Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
EP3169310A1 (de)	2014-07-15	2017-05-24	Life Technologies Corporation	Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5034506A (en) *	1985-03-15	1991-07-23	Anti-Gene Development Group	Uncharged morpholino-based polymers having achiral intersubunit linkages
US5194428A (en) *	1986-05-23	1993-03-16	Worcester Foundation For Experimental Biology	Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US4806463A (en) *	1986-05-23	1989-02-21	Worcester Foundation For Experimental Biology	Inhibition of HTLV-III by exogenous oligonucleotides
US5004810A (en) *	1988-09-30	1991-04-02	Schering Corporation	Antiviral oligomers
US5098890A (en) *	1988-11-07	1992-03-24	Temple University-Of The Commonwealth System Of Higher Education	Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5087617A (en) *	1989-02-15	1992-02-11	Board Of Regents, The University Of Texas System	Methods and compositions for treatment of cancer using oligonucleotides
US5639595A (en) *	1990-05-01	1997-06-17	Isis Phamaceuticals, Inc.	Identification of novel drugs and reagents
US5166195A (en) *	1990-05-11	1992-11-24	Isis Pharmaceuticals, Inc.	Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5135917A (en) *	1990-07-12	1992-08-04	Nova Pharmaceutical Corporation	Interleukin receptor expression inhibiting antisense oligonucleotides
US5489519A (en) *	1992-10-27	1996-02-06	Queen's University At Kingston	Multidrug resistance protein

1993
- 1993-10-18 US US08/136,811 patent/US5510239A/en not_active Expired - Lifetime
1994
- 1994-09-23 AU AU79582/94A patent/AU678628B2/en not_active Ceased
- 1994-09-23 CA CA002174315A patent/CA2174315C/en not_active Expired - Fee Related
- 1994-09-23 DE DE69432934T patent/DE69432934T2/de not_active Expired - Fee Related
- 1994-09-23 JP JP7511828A patent/JP2937481B2/ja not_active Expired - Lifetime
- 1994-09-23 AT AT94930472T patent/ATE244506T1/de not_active IP Right Cessation
- 1994-09-23 WO PCT/US1994/010827 patent/WO1995010938A1/en not_active Ceased
- 1994-09-23 EP EP94930472A patent/EP0788307B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US5510239A (en)	1996-04-23
AU7958294A (en)	1995-05-08
DE69432934T2 (de)	2004-04-22
AU678628B2 (en)	1997-06-05
CA2174315C (en)	2001-08-21
EP0788307B1 (de)	2003-07-09
EP0788307A1 (de)	1997-08-13
DE69432934D1 (de)	2003-08-14
JP2937481B2 (ja)	1999-08-23
WO1995010938A1 (en)	1995-04-27
CA2174315A1 (en)	1995-04-27
JPH09503391A (ja)	1997-04-08
EP0788307A4 (de)	1998-12-23

Legal Events

Date	Code	Title	Description
2004-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE244506T1 (de)	2003-07-15	Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein
ATE212063T1 (de)	2002-02-15	Oligonukleotide modulation von protein kinase c
ATE289200T1 (de)	2005-03-15	Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
ATE231915T1 (de)	2003-02-15	Beeinflussing der zelladhäsie durch oligonukleotide
NO965080D0 (no)	1996-11-28	Antisens oligonukleotidmodulering av genekspresjon
EP0527818A4 (en)	1993-09-15	Oligonucleotide modulation of arachidonic acid metabolism
BR9206049A (pt)	1994-12-27	Composto, processos para preparar o composto, para o reconhecimento específico por sequência de um polinucleotídio de filamento duplo, para modular a expressão de um gene em um organismo, para tratar as condições associadas com produção de proteínas indesejada em um organismo, para induzir a degradação de DNA ou RNA em células de um organismo e para exterminar células ou vírus e composição farmacêutica
ATE465261T1 (de)	2010-05-15	Integrin-gekoppelte kinase, ihre hemmstoffe und deren gebrauch für verfahren zur therapeutischen behandlung; gentherapie und bereitstellung von hemmstoffen, die als pseudosubstrate wirken
ATE230023T1 (de)	2003-01-15	Beeinflussung der zelladhäsion durch oligonukleotide
EP1185696A4 (de)	2003-04-16	Modifikation der expression der menschlichen proteinkinase c-delta mit hilfe von antisense-oligonukleotiden
WO2000030590A3 (en)	2000-08-17	Methods and compositions for diagnosis and treatment of cancer based on the transcription factor ets2
WO2003040320A3 (en)	2004-08-19	Antisense modulation of human collapsin response mediator protein 2 expression